Cancer cachexia rarely announces itself as a single problem. It begins as a system-wide shift: inflammatory signaling that drives appetite loss, muscle breakdown, and progressive weight loss. Anamorelin hydrochloride approaches that cascade at the receptor level. It is not a peptide. It is a small, orally active molecule that acts like a ghrelin mimetic, selectively agonizing the growth hormone secretagogue receptor 1a, the same target discussed for MK-677.

Because the receptor sits in both the hypothalamus and the anterior pituitary, anamorelin influences two pathways at once. In the arcuate nucleus it stimulates orexigenic NPY and AgRP neurons while inhibiting anorexigenic POMC and CART neurons, driving hunger signaling. At the pituitary it triggers dose-dependent growth hormone release, which raises IGF-1 and IGF binding protein 3 within physiologic range and supports skeletal protein synthesis through PI3K, AKT, and mTOR.

Dosing in the trials was 100 mg orally once daily, taken on an empty stomach before a meal, with roughly two hours fasted beforehand and about thirty minutes after. Monitoring includes body weight, blood glucose and HbA1c, IGF-1, hepatic enzymes, appetite scoring, and the neutrophil-to-lymphocyte ratio at baseline, four weeks, and twelve weeks. Hyperglycemia appeared in under five percent of patients, and adverse events rose past age 75.

Anamorelin is supportive, not a cancer treatment. It is studied as one element of a multimodal plan alongside effective anti-tumor therapy, high-protein nutrition, omega-3 fatty acids, and resistance training.

Key clinical points

• Approval status: Approved in Japan in 2021 for cachexia in non-small-cell lung, gastric, pancreatic, and colorectal cancers. Not approved by the FDA or the EMA. The half-life is six to seven hours with rapid oral absorption.
• Mass without strength: Phase II and III trials showed increases in lean body mass, with one study reporting a 1.56 kg gain at 100 mg measured by DEXA. Hand-grip strength did not improve significantly, the gap that led the EMA to decline approval.
• Why strength lagged: Active cancer generates cytokines that work against muscle contractility. Building lean mass is a meaningful starting point, but resistance exercise is needed to translate that mass into function.
• Anti-inflammatory mechanism: Signaling reduced TNF-alpha and IL-6 by modulating NF-kB activity, the same cytokines that drive cachexia. Across controlled trials, no acceleration of tumor progression was observed.
• Patient selection: Best candidates show greater than five percent involuntary weight loss in six months or BMI under 20, are under 75, and carry a neutrophil-to-lymphocyte ratio below 4.4, a predictor of better response.